Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
ANCA vasculitis may trigger inflammation in large blood vessels as well as the small ones the disease is associated with, Japanese researchers reported after noting that three patients had developed an ... Read more
The European Medicines Agency (EMA) has accepted for review ChemoCentryx’s application to approve Avacopan (CCX168) as a treatment for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The company, with its partner Vifor ... Read more
A clinical trial will assess whether low-dose glucocorticoids and Rituxan (rituximab) may be used as a safer way to treat ANCA-associated vasculitis (AAV). Researchers at Chiba University Hospital in Japan believe ... Read more
While the treatment of ANCA-associated vasculitis has taken strides away from highly toxic immunosuppressants to include an array of approaches based on biological drugs, there is plenty of room for ... Read more
Certain types of patients with ANCA-associated vasculitis do not require maintenance therapy if treated with a specific Rituxan (rituximab) approach, according to researchers at the University of Turin in Italy ... Read more
People with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis have a lesser chance of relapse if they continue with maintenance treatment for two years instead of one, according to the results of ... Read more
Nucala (mepolizumab) effectively induced remission in about half of patients with eosinophilic granulomatosis with polyangiitis (EGPA) that relapsed or did not respond to treatment, according to results from a Phase ... Read more